Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106800025> ?p ?o ?g. }
- W2106800025 endingPage "1213" @default.
- W2106800025 startingPage "1209" @default.
- W2106800025 abstract "Purpose To report the outcome of oral chlorambucil as a single treatment in patients with orbital mucosa-associated lymphoid tissue (MALT) lymphoma. Design Retrospective nonrandomized clinical study. Participants Thirty-three patients with isolated orbital MALT lymphoma. Methods Medical records of all patients with histology-verified orbital MALT lymphoma treated with oral chlorambucil at the Royal Melbourne Hospital were reviewed. Main Outcome Measures Complete clinical response, partial response, local relapse, systemic extension (distant relapse), and survival. Results Thirty-three patients (19 female; mean age, 69 years) participated in the study. Patients received an average of 4 courses of oral chlorambucil with a mean total dose of 600 mg. The lacrimal gland was the most frequent site of occurrence (24%), followed by the conjunctiva, eyelid, and superior orbit. Orbital mass, swelling, and diplopia were common presenting signs. Complete response was noted in 26 patients (79%). In 2 of the patients with complete clinical response, mild residual thickening was noted on follow-up orbital imaging studies. Four patients (12%) showed disease recurrence or relapse. Mean follow-up time was 32 (±20) months (range, 8 months–6 years; median, 26 months). None of the patients developed granulocytopenia secondary to chemotherapy, and none suffered significant nausea or vomiting. One patient with malignant transformation died 12 months after diagnosis and initial treatment. Conclusions Systemic chemotherapy with chlorambucil is a reasonable option in patients with orbital MALT lymphoma. It is associated with minimal to no side effects. Additionally, it may be well tolerated by elderly patients and also may treat subclinical disease elsewhere. To report the outcome of oral chlorambucil as a single treatment in patients with orbital mucosa-associated lymphoid tissue (MALT) lymphoma. Retrospective nonrandomized clinical study. Thirty-three patients with isolated orbital MALT lymphoma. Medical records of all patients with histology-verified orbital MALT lymphoma treated with oral chlorambucil at the Royal Melbourne Hospital were reviewed. Complete clinical response, partial response, local relapse, systemic extension (distant relapse), and survival. Thirty-three patients (19 female; mean age, 69 years) participated in the study. Patients received an average of 4 courses of oral chlorambucil with a mean total dose of 600 mg. The lacrimal gland was the most frequent site of occurrence (24%), followed by the conjunctiva, eyelid, and superior orbit. Orbital mass, swelling, and diplopia were common presenting signs. Complete response was noted in 26 patients (79%). In 2 of the patients with complete clinical response, mild residual thickening was noted on follow-up orbital imaging studies. Four patients (12%) showed disease recurrence or relapse. Mean follow-up time was 32 (±20) months (range, 8 months–6 years; median, 26 months). None of the patients developed granulocytopenia secondary to chemotherapy, and none suffered significant nausea or vomiting. One patient with malignant transformation died 12 months after diagnosis and initial treatment. Systemic chemotherapy with chlorambucil is a reasonable option in patients with orbital MALT lymphoma. It is associated with minimal to no side effects. Additionally, it may be well tolerated by elderly patients and also may treat subclinical disease elsewhere." @default.
- W2106800025 created "2016-06-24" @default.
- W2106800025 creator A5046242179 @default.
- W2106800025 creator A5052472315 @default.
- W2106800025 creator A5058655343 @default.
- W2106800025 creator A5071699571 @default.
- W2106800025 creator A5073049108 @default.
- W2106800025 date "2006-07-01" @default.
- W2106800025 modified "2023-09-24" @default.
- W2106800025 title "Oral Chlorambucil for Extranodal, Marginal Zone, B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue of the Orbit" @default.
- W2106800025 cites W1538281804 @default.
- W2106800025 cites W1856283124 @default.
- W2106800025 cites W1860596162 @default.
- W2106800025 cites W1967724532 @default.
- W2106800025 cites W1967904730 @default.
- W2106800025 cites W1970083422 @default.
- W2106800025 cites W1994197048 @default.
- W2106800025 cites W2014852451 @default.
- W2106800025 cites W2031328526 @default.
- W2106800025 cites W2032258534 @default.
- W2106800025 cites W2041366039 @default.
- W2106800025 cites W2052861764 @default.
- W2106800025 cites W2058488029 @default.
- W2106800025 cites W2074136452 @default.
- W2106800025 cites W2075951226 @default.
- W2106800025 cites W2079485481 @default.
- W2106800025 cites W2079612357 @default.
- W2106800025 cites W2083674625 @default.
- W2106800025 cites W2087862155 @default.
- W2106800025 cites W2088332148 @default.
- W2106800025 cites W2089326169 @default.
- W2106800025 cites W2096617875 @default.
- W2106800025 cites W2102096611 @default.
- W2106800025 cites W2107202569 @default.
- W2106800025 cites W2108508102 @default.
- W2106800025 cites W2112173610 @default.
- W2106800025 cites W2112387181 @default.
- W2106800025 cites W2121876728 @default.
- W2106800025 cites W2136596222 @default.
- W2106800025 cites W2138241730 @default.
- W2106800025 cites W2144574383 @default.
- W2106800025 cites W2148613364 @default.
- W2106800025 cites W2154494821 @default.
- W2106800025 cites W2157065628 @default.
- W2106800025 cites W2171625299 @default.
- W2106800025 cites W2338573834 @default.
- W2106800025 cites W4239464349 @default.
- W2106800025 cites W82942945 @default.
- W2106800025 doi "https://doi.org/10.1016/j.ophtha.2006.01.057" @default.
- W2106800025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16647129" @default.
- W2106800025 hasPublicationYear "2006" @default.
- W2106800025 type Work @default.
- W2106800025 sameAs 2106800025 @default.
- W2106800025 citedByCount "76" @default.
- W2106800025 countsByYear W21068000252012 @default.
- W2106800025 countsByYear W21068000252013 @default.
- W2106800025 countsByYear W21068000252014 @default.
- W2106800025 countsByYear W21068000252015 @default.
- W2106800025 countsByYear W21068000252016 @default.
- W2106800025 countsByYear W21068000252017 @default.
- W2106800025 countsByYear W21068000252018 @default.
- W2106800025 countsByYear W21068000252019 @default.
- W2106800025 countsByYear W21068000252020 @default.
- W2106800025 countsByYear W21068000252021 @default.
- W2106800025 countsByYear W21068000252022 @default.
- W2106800025 countsByYear W21068000252023 @default.
- W2106800025 crossrefType "journal-article" @default.
- W2106800025 hasAuthorship W2106800025A5046242179 @default.
- W2106800025 hasAuthorship W2106800025A5052472315 @default.
- W2106800025 hasAuthorship W2106800025A5058655343 @default.
- W2106800025 hasAuthorship W2106800025A5071699571 @default.
- W2106800025 hasAuthorship W2106800025A5073049108 @default.
- W2106800025 hasConcept C126322002 @default.
- W2106800025 hasConcept C141071460 @default.
- W2106800025 hasConcept C159654299 @default.
- W2106800025 hasConcept C203014093 @default.
- W2106800025 hasConcept C2776694085 @default.
- W2106800025 hasConcept C2776755627 @default.
- W2106800025 hasConcept C2777866208 @default.
- W2106800025 hasConcept C2778453870 @default.
- W2106800025 hasConcept C2778563104 @default.
- W2106800025 hasConcept C2779338263 @default.
- W2106800025 hasConcept C2779526237 @default.
- W2106800025 hasConcept C2779851268 @default.
- W2106800025 hasConcept C2779921676 @default.
- W2106800025 hasConcept C2780580376 @default.
- W2106800025 hasConcept C2780581723 @default.
- W2106800025 hasConcept C71924100 @default.
- W2106800025 hasConcept C90924648 @default.
- W2106800025 hasConceptScore W2106800025C126322002 @default.
- W2106800025 hasConceptScore W2106800025C141071460 @default.
- W2106800025 hasConceptScore W2106800025C159654299 @default.
- W2106800025 hasConceptScore W2106800025C203014093 @default.
- W2106800025 hasConceptScore W2106800025C2776694085 @default.
- W2106800025 hasConceptScore W2106800025C2776755627 @default.
- W2106800025 hasConceptScore W2106800025C2777866208 @default.
- W2106800025 hasConceptScore W2106800025C2778453870 @default.
- W2106800025 hasConceptScore W2106800025C2778563104 @default.